The Pilot Signal Management Expert Group (P-SMEG) coordinates the signal management process for veterinary medicines authorised in the European Union (EU). This entails activities to determine if there are new risks associated with a medicine, such as side effects.

The main objectives of this expert group include:

  • setting up and testing new signal management processes;
  • building a sustainable regulatory framework to implement the provisions of the Veterinary Medicinal Products Regulation (Regulation (EU) 2019/6) related to signal management.

The P-SMEG is an expert group established with the Heads of Medicines Agencies (HMA) and under the Pharmacovigilance Working Party (PhVWP-V).

The P-SMEG's tasks include:

  • identifying, prioritising and assessing safety issues for veterinary medicines by reviewing pharmacovigilance data for safety signals;
  • proposing regulatory actions to the PhVWP-V based on detected safety signals;
  • preparing and providing training to national competent authorities.

EMA and HMA set up this expert group in January 2022. It is running as a pilot for an initial period of 2 years. EMA will make the results of this pilot public.

Composition

The P-SMEG is composed of 12 European experts, including 11 experts nominated by the national competent authorities and 1 expert nominated by the PhVWP-V.

Members

Below (in alphabetical order of the surname) are the current members of the expert group. The members' declarations of interests are available in the European expert list.

Share this page